05 Avr APRIL 2018: Holimel® clinical and preclinical results are now published!
We are pleased to share our newest scientific paper, presenting the results of Holimel® clinical and preclinical studies on UV protection. Randomized, double-blind and placebo controlled, this trial highlighted Holimel® ability to significantly increase Minimal Erythema Dose (MED), after just 4 days of topical administration and/or 1 month of oral supplementation.
Those results were additionally supported by a trial assessed on human skin explants, which demonstrated Holimel® capacity to prevent the occurrence of sunburn cells, decrease melanin levels and boost the skin’s own antioxidant enzymes.
Clinically proven to protect the skin against UV-associated damage, Holimel® is a unique and effective solution for a daily protection against exogenous threats and associated premature ageing.